Zeitschriftenartikel zum Thema „Metastatic papillary renal-Cell cancer“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Metastatic papillary renal-Cell cancer" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Sidana, Abhinav, Amit L. Jain, Meet Kadakia, Spencer Krane, Julia C. Friend, Akhil Muthigi, Martha Ninos, Joanna H. Shih und Ramaprasad Srinivasan. „Predictors of mortality in metastatic papillary renal cell cancer.“ Journal of Clinical Oncology 35, Nr. 6_suppl (20.02.2017): 509. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.509.
Der volle Inhalt der QuelleCarlo, Maria Isabel, Nabeela Khan, Yingbei Chen, James Hsieh, A. Ari Hakimi, Chung-Han Lee, Darren R. Feldman, Robert J. Motzer und Martin Henner Voss. „The genomic landscape of metastatic non-clear cell renal cell carcinoma.“ Journal of Clinical Oncology 35, Nr. 6_suppl (20.02.2017): 474. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.474.
Der volle Inhalt der QuelleGraham, Jeffrey, Connor Wells, Frede Donskov, Jae-Lyun Lee, Anna Paola Fraccon, Felice Pasini, Camillo Porta et al. „Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).“ Journal of Clinical Oncology 36, Nr. 6_suppl (20.02.2018): 581. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.581.
Der volle Inhalt der QuelleDudani, Shaan, Guillermo de Velasco, Connor Wells, Chun Loo Gan, Frede Donskov, Camillo Porta, Anna Fraccon et al. „Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma.“ Journal of Clinical Oncology 38, Nr. 15_suppl (20.05.2020): 5071. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5071.
Der volle Inhalt der QuelleMotzer, Robert J., Jennifer Bacik, Tania Mariani, Paul Russo, Madhu Mazumdar und Victor Reuter. „Treatment Outcome and Survival Associated With Metastatic Renal Cell Carcinoma of Non–Clear-Cell Histology“. Journal of Clinical Oncology 20, Nr. 9 (01.05.2002): 2376–81. http://dx.doi.org/10.1200/jco.2002.11.123.
Der volle Inhalt der QuelleRonnen, Ellen A., G. Varuni Kondagunta, Nicole Ishill, Lesley Spodek, Paul Russo, Victor Reuter, Jennifer Bacik und Robert J. Motzer. „Treatment outcome for metastatic papillary renal cell carcinoma patients“. Cancer 107, Nr. 11 (2006): 2617–21. http://dx.doi.org/10.1002/cncr.22340.
Der volle Inhalt der QuelleElabbady, Ahmed, Ryan Boudreau und Vahid Mehrnoush. „Rapid metachronous bladder metastasis of type 2 papillary renal cell carcinoma“. Archive of Clinical Cases 10, Nr. 2 (18.05.2023): 93–96. http://dx.doi.org/10.22551/2023.39.1002.10249.
Der volle Inhalt der QuelleSteiner, T., J. Roigas, H. Kirchner, C. Doehn, H. Heynemann, M. Siebels, S. Loening et al. „Clinical course of patients with metastatic papillary renal cell carcinoma“. Journal of Clinical Oncology 24, Nr. 18_suppl (20.06.2006): 14591. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.14591.
Der volle Inhalt der QuelleYonese, Ichiro, Masaya Ito, Kosuke Takemura, Takao Kamai und Fumitaka Koga. „A Case of Metastatic Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome-Associated Renal Cell Carcinoma Treated with a Sequence of Axitinib and Nivolumab Following Cytoreductive Nephrectomy“. Journal of Kidney Cancer and VHL 7, Nr. 2 (20.07.2020): 6–10. http://dx.doi.org/10.15586/jkcvhl.2020.148.
Der volle Inhalt der QuelleSchrader, A. J., S. Rauer-Bruening, P. J. Olbert, A. Hegele, J. Rustemeier und R. Hofmann. „Incidence and long term prognosis of papillary renal cell carcinoma“. Journal of Clinical Oncology 27, Nr. 15_suppl (20.05.2009): e16020-e16020. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e16020.
Der volle Inhalt der QuelleFriend, Julia C., Daniel Su, Rashmi Thimmapuram, James Peterson, Geri Hawks, Martha Ninos, W. Marston Linehan und Ramaprasad Srinivasan. „Malignant ascites as a manifestation of advanced papillary renal cell cancer (pRCC).“ Journal of Clinical Oncology 33, Nr. 7_suppl (01.03.2015): 465. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.465.
Der volle Inhalt der QuelleWells, J. Connor, Frede Donskov, Anna Paola Fraccon, Felice Pasini, Georg A. Bjarnason, Jennifer J. Knox, Benoit Beuselinck et al. „Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC).“ Journal of Clinical Oncology 34, Nr. 15_suppl (20.05.2016): 4554. http://dx.doi.org/10.1200/jco.2016.34.15_suppl.4554.
Der volle Inhalt der QuelleSomorácz, Áron, Levente Kuthi, Tamás Micsik, Alex Jenei, Adrienn Hajdu, Brigitta Vrabély, Erzsébet Rásó et al. „Renal Cell Carcinoma with Clear Cell Papillary Features: Perspectives of a Differential Diagnosis“. Pathology & Oncology Research 26, Nr. 3 (26.10.2019): 1767–76. http://dx.doi.org/10.1007/s12253-019-00757-3.
Der volle Inhalt der QuelleBarua, Sasanka K., Sarbartha K. Pratihar, Pranab K. Kaman, Atul Garg, Rajeev T. P., Saumar J. Baruah, Puskal K. Bagchi, Debanga Sarma und Mandeep Phukan. „Cervical lymphadenopathy as initial presentation of genito-urinary cancer“. International Journal of Otorhinolaryngology and Head and Neck Surgery 5, Nr. 6 (23.10.2019): 1739. http://dx.doi.org/10.18203/issn.2454-5929.ijohns20194964.
Der volle Inhalt der QuelleStenman, Maria, Andreas Demetrios Nearchou, Per Sandström, Magnus Lindskog und Ulrika Harmenberg. „Metastatic papillary renal cell carcinoma: A retrospective study from two large academic centers in Sweden.“ Journal of Clinical Oncology 34, Nr. 2_suppl (10.01.2016): 535. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.535.
Der volle Inhalt der QuellePark, Sang Hyun, Taek Sang Kim, Jae Young Joung, Sung Han Kim und Jinsoo Chung. „Postoperative long-term prognosis of localized renal cell carcinoma after partial or radical nephrectomy: Analysis of cancer metastasis and deaths during a more than five-year follow-up.“ Journal of Clinical Oncology 37, Nr. 7_suppl (01.03.2019): 604. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.604.
Der volle Inhalt der QuelleZielli, Teresa, Letizia Gnetti und Sebastiano Buti. „Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report“. Tumori Journal 106, Nr. 6 (27.05.2020): NP79—NP83. http://dx.doi.org/10.1177/0300891620924472.
Der volle Inhalt der QuelleArmstrong, Andrew J., Susan Halabi, Tim Eisen, Walter Michael Stadler, Robert R. Jones, Ulka N. Vaishampayan, Jorge A. Garcia et al. „ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma.“ Journal of Clinical Oncology 31, Nr. 15_suppl (20.05.2013): TPS4590. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.tps4590.
Der volle Inhalt der QuelleShuch, Brian, Lambros Stamatakis, Clara Chen, Rabindra Gautam, Maria Merino, Peter L. Choyke, W. Marston Linehan und Ramaprasad Srinivasan. „Utility of 2-(18F) fluoro-2 deoxy-D-glucose PET/CT in advanced papillary renal cell carcinoma.“ Journal of Clinical Oncology 32, Nr. 4_suppl (01.02.2014): 419. http://dx.doi.org/10.1200/jco.2014.32.4_suppl.419.
Der volle Inhalt der QuelleDidwaniya, N., R. J. Edmonds, X. Fang, P. T. Silberstein und S. Subbiah. „Survival outcomes in metastatic renal carcinoma based on histological subtypes: SEER database analysis.“ Journal of Clinical Oncology 29, Nr. 7_suppl (01.03.2011): 381. http://dx.doi.org/10.1200/jco.2011.29.7_suppl.381.
Der volle Inhalt der Quellede Vries-Brilland, Manon, Nathalie Rioux-Leclercq, Maxime Meylan, Jonathan Dauvé, Christophe Passot, Elena Spirina-Menand, Ronan Flippot et al. „Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma“. Journal for ImmunoTherapy of Cancer 11, Nr. 11 (November 2023): e006885. http://dx.doi.org/10.1136/jitc-2023-006885.
Der volle Inhalt der QuelleMcKay, Rana R., Pedro C. Barata, Andrew Elliott, Mehmet Asim Bilen, Earle F. Burgess, Sourat Darabi, Nancy Ann Dawson et al. „Molecular alterations across sites of metastasis in patients with renal cell carcinoma (RCC).“ Journal of Clinical Oncology 40, Nr. 6_suppl (20.02.2022): 287. http://dx.doi.org/10.1200/jco.2022.40.6_suppl.287.
Der volle Inhalt der QuelleBambury, Richard Martin, Claire Brady, Aoife McCarthy, Stewart Fleming, Nicholas J. Mayer und Derek Gerard Power. „Translocation renal cell carcinomas: An evolving entity.“ Journal of Clinical Oncology 30, Nr. 5_suppl (10.02.2012): 472. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.472.
Der volle Inhalt der QuelleEldessouki, Ihab, Ola Gaber, Mahmoud A. Shehata, Tariq Namad, Joseph Atallah, Harsha Masineni und Nagla Abdel Karim. „Papillary renal cell carcinoma: what is missing in research? A case report and a review of literature“. SAGE Open Medical Case Reports 7 (Januar 2019): 2050313X1986947. http://dx.doi.org/10.1177/2050313x19869475.
Der volle Inhalt der QuelleSu, Daniel, Chinonyerem Okoro, Arvin George, W. Marston Linehan und Adam R. Metwalli. „Bilateral multifocal papillary type I renal cell carcinoma: Clinical characteristics and association with chronic renal insufficiency.“ Journal of Clinical Oncology 32, Nr. 4_suppl (01.02.2014): 482. http://dx.doi.org/10.1200/jco.2014.32.4_suppl.482.
Der volle Inhalt der QuelleAgarwala, Vivek, Anant Ramaswamy, Amit Joshi, Vijay Maruti Patil, Vanita Noronha, Santosh Menon, B. Palak Popat, Sable Nilesh und Kumar Prabhash. „Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis“. South Asian Journal of Cancer 07, Nr. 04 (Oktober 2018): 226–30. http://dx.doi.org/10.4103/sajc.sajc_22_18.
Der volle Inhalt der QuelleEssam, Abdul Monem, Ajit Venniyoor, Suresh Nagdev, Itrat Mehdi und Bassim Al Bahrani. „Long-term survival in a case of metastatic papillary renal cell carcinoma“. South Asian Journal of Cancer 06, Nr. 01 (Januar 2017): 019–34. http://dx.doi.org/10.4103/2278-330x.202562.
Der volle Inhalt der QuelleYamazaki, Haruhiko, Takeshi Kishida, Go Noguchi, Hiroyuki Iwasaki, Nobuyasu Suganuma, Katsuhiko Masudo, Hirotaka Nakayama et al. „Nephrectomy for Metastatic Kidney Tumor in Patients with Differentiated Thyroid Cancer: A Report of Two Cases“. Case Reports in Endocrinology 2018 (11.11.2018): 1–5. http://dx.doi.org/10.1155/2018/7842792.
Der volle Inhalt der QuelleVoss, Martin Henner, Yingbei Chen, Joshua Chaim, Devyn Taylor Coskey, Kaitlin Woo, Sujata Patil, Ana M. Molina, James Hsieh, Robert J. Motzer und Darren Richard Feldman. „A phase II trial of everolimus and bevacizumab in advanced non-clear cell renal cell cancer.“ Journal of Clinical Oncology 33, Nr. 7_suppl (01.03.2015): 411. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.411.
Der volle Inhalt der QuelleLam, J. S., R. H. Goel, A. J. Pantuck, R. A. Figlin und A. S. Belldegrun. „Long-term survival following nephrectomy for renal cell carcinoma: The 15 year University of California-Los Angeles experience“. Journal of Clinical Oncology 24, Nr. 18_suppl (20.06.2006): 14532. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.14532.
Der volle Inhalt der QuellePeters, Inga, Christel Reese, Natalia Dubrowinskaja, Wiebke Inga Antonopoulos, Martin Krause, Tu Nghi Dang, Alexander Grote et al. „DNA methylation signature for the assessment of metastatic risk in primary renal cell cancer.“ Journal of Clinical Oncology 35, Nr. 6_suppl (20.02.2017): 516. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.516.
Der volle Inhalt der QuelleChoueiri, Toni K., Anne Plantade, Paul Elson, Sylvie Negrier, Alain Ravaud, Stephane Oudard, Ming Zhou, Brian I. Rini, Ronald M. Bukowski und Bernard Escudier. „Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma“. Journal of Clinical Oncology 26, Nr. 1 (01.01.2008): 127–31. http://dx.doi.org/10.1200/jco.2007.13.3223.
Der volle Inhalt der QuelleVoss, Martin H., Ana M. Molina, Ying-Bei Chen, Kaitlin M. Woo, Joshua L. Chaim, Devyn T. Coskey, Almedina Redzematovic et al. „Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non–Clear Cell Renal Cell Carcinoma“. Journal of Clinical Oncology 34, Nr. 32 (10.11.2016): 3846–53. http://dx.doi.org/10.1200/jco.2016.67.9084.
Der volle Inhalt der QuellePower, Derek Gerard, Jodie E. Battley, Aoife McCarthy, Claire Brady, John P. Sweeney, Stewart Fleming, Nicholas J. Mayer und Richard Martin Bambury. „Translocation renal cell carcinomas: An evolving entity.“ Journal of Clinical Oncology 30, Nr. 15_suppl (20.05.2012): e15078-e15078. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e15078.
Der volle Inhalt der QuelleTsimafeyeu, Ilya, Alexandra Naumova, Evgenia Stepanova, Alfia Khasanova, Ilya Varlamov, Nigel Wynn, Anton Snegovoy und Lev V. Demidov. „FGFR2 expression to predict survival outcome in patients with metastatic papillary renal cell carcinoma.“ Journal of Clinical Oncology 34, Nr. 2_suppl (10.01.2016): 506. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.506.
Der volle Inhalt der QuelleNicaise, Edouard, Benjamin Schmeusser, Adil Ali, Eric Midenberg, Arnold Raul Palacios, Ethan Kearns, Sriram Ambadi et al. „Linear muscle segmentation for metastatic renal cell carcinoma.“ Journal of Clinical Oncology 42, Nr. 4_suppl (01.02.2024): 380. http://dx.doi.org/10.1200/jco.2024.42.4_suppl.380.
Der volle Inhalt der QuelleMorinaga, Ryota, Takashi Kawahara, Yasuhide Miyoshi, Masahiro Yao und Hiroji Uemura. „Longer Control of Nivolumab in Metastatic Renal Cell Carcinoma Patients with End-Stage Kidney Disease on Dialysis“. Case Reports in Oncology 12, Nr. 2 (06.08.2019): 608–12. http://dx.doi.org/10.1159/000501768.
Der volle Inhalt der QuelleAlbiges, Laurence, Daniel Yick Chin Heng, Jae-Lyun Lee, Stephen Walker, Anders Mellemgaard, Lone Ottesen, Melanie M. Frigault et al. „MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data.“ Journal of Clinical Oncology 38, Nr. 15_suppl (20.05.2020): e19321-e19321. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19321.
Der volle Inhalt der QuelleMoreira, Raphael Brandao, Rana R. McKay, Wanling Xie, Daniel Yick Chin Heng, Guillermo de Velasco, Daniel E. Castellano, Andre Poisl Fay et al. „Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC).“ Journal of Clinical Oncology 35, Nr. 6_suppl (20.02.2017): 482. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.482.
Der volle Inhalt der QuelleHeng, Daniel Y. C., und Toni K. Choueiri. „Non–Clear Cell Renal Cancer: Features and Medical Management“. Journal of the National Comprehensive Cancer Network 7, Nr. 6 (Juni 2009): 659–65. http://dx.doi.org/10.6004/jnccn.2009.0046.
Der volle Inhalt der QuelleBodard, Sylvain, Idris Boudhabhay, Charles Dariane, Christophe Delavaud, Sylvain Guinebert, Dominique Joly, Marc-Olivier Timsit et al. „Percutaneous Thermal Ablation for Renal Tumors in Patients with Birt–Hogg–Dubé Syndrome“. Cancers 14, Nr. 20 (11.10.2022): 4969. http://dx.doi.org/10.3390/cancers14204969.
Der volle Inhalt der Quellevon Klot, Christoph A. J., Natalia Dubrowinskaja, Jörg Hennenlotter, Mario W. Kramer, Axel S. Merseburger, Arnulf Stenzl, Inga Peters, Hossein Tezval, Markus A. Kuczyk und Juergen Serth. „Rho GDP dissociation inhibitor beta ARHGDIB in renal cell cancer.“ Journal of Clinical Oncology 33, Nr. 7_suppl (01.03.2015): 474. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.474.
Der volle Inhalt der QuelleTsimafeyeu, I., A. Khasanova, E. Stepanova, M. Gordiev, D. Khochenkov, A. Naumova, I. Varlamov, A. Snegovoy und L. Demidov. „FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma“. Clinical and Translational Oncology 19, Nr. 2 (05.07.2016): 265–68. http://dx.doi.org/10.1007/s12094-016-1524-y.
Der volle Inhalt der QuelleSawyer, Reed, und Harris Wayne B. „Clinical implications of epigenetics in Renal Cell Carcinoma“. Archives of Renal Diseases and Management 7, Nr. 1 (27.07.2022): 008–13. http://dx.doi.org/10.17352/2455-5495.000040.
Der volle Inhalt der QuelleMarchand Crety, Charles, Estelle Vigneau und Camille Invernizzi. „Stereotactic Body Radiotherapy of a Solitary Metachronous Sphenoid Metastasis from Renal Cell Cancer: A Case Report“. Case Reports in Oncology 14, Nr. 1 (02.03.2021): 269–73. http://dx.doi.org/10.1159/000513743.
Der volle Inhalt der QuelleAhrens, Marit, Bernard Escudier, John B. A. G. Haanen, Ekaterini Boleti, Marine Gross Goupil, Marc-Oliver Grimm, Sylvie Negrier et al. „A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).“ Journal of Clinical Oncology 39, Nr. 15_suppl (20.05.2021): TPS4597. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.tps4597.
Der volle Inhalt der QuelleAhrens, Marit, Bernard Escudier, Ekaterini Boleti, Marc-Oliver Grimm, Marine Gross-Goupil, Philippe Barthelemy, Gwenaelle Gravis et al. „A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).“ Journal of Clinical Oncology 38, Nr. 15_suppl (20.05.2020): TPS5103. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps5103.
Der volle Inhalt der QuelleCasuscelli, Jozefina, Andrew G. Winer, Eduard Reznik, Jianing Xu, Brandon Manley, Jyoti Chouhan, Victor E. Reuter et al. „Single-institutional analysis of patients with clear-cell papillary renal cell carcinoma.“ Journal of Clinical Oncology 34, Nr. 2_suppl (10.01.2016): 512. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.512.
Der volle Inhalt der QuelleGrenader, Tal, Eli Rosenbaum, Sofia Zilber, Naama Bogot und Linda Shavit. „Spontaneous Regression of Metastatic Papillary Renal Cell Cancer After Cessation of Treatment With Sorafenib“. Clinical Genitourinary Cancer 11, Nr. 2 (Juni 2013): 201–3. http://dx.doi.org/10.1016/j.clgc.2012.11.005.
Der volle Inhalt der QuellePrager, Gerald, und Marina Poettler. „CD98hc expression to predict prognosis in renal cell cancer.“ Journal of Clinical Oncology 30, Nr. 30_suppl (20.10.2012): 26. http://dx.doi.org/10.1200/jco.2012.30.30_suppl.26.
Der volle Inhalt der Quelle